Mechanistic Insights into the Diabetes–Cirrhosis–Hepatocellular Carcinoma Axis: Molecular Mechanisms and Therapeutic Perspectives
Journal of Cancer Biomoleculars and Therapeutics · 17.06.2026 · 3 (2) · 35-49
DOI: 10.62382/jcbt.v3i2.117 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cancer Biomoleculars and Therapeutics, online erschienen am 17.06.2026. Verfasst von Chaman Ara und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) cellular metabolism is also directed toward glycolysis in order to improve the synthesis of metabolic chemicals utilized by cancer cells to produce proteins, lipids, and nucleotides and maintain a high rate of cell proliferation. Several hepatic conditions are strongly associated with diabetes mellitus (DM), including non-alcoholic fatty liver disease (NAFLD), steatohepatitis, and liver cirrhosis. Recent findings also support that DM can predispose individuals to various forms of malignant neoplasm including renal, endometrial, breast, gallbladder, colorectal, pancreatic, and liver cancer likewise the HCC. This process promotes uncontrolled cellular proliferation and increases reactive oxygen species (ROS) production, contributing to cellular damage, which may cause cell death. Numerous risk factors of both DM and cancer share so much, yet the relationship between the two is imprecisely stated. Some epidemiologic studies have established a correlation between pathogenic and prognostic attributes of DM and increased incidence of HCC and, therefore, depict DM as a single risk factor in the development of HCC. The etiological and pathophysiological relationship between DM and HCC has been given in this review, which links hyperglycemia, hyperinsulinemia, insulin resistance, and the activation of insulin-like growth factor (IGF) signaling pathway and pharmacological treatment of the HCC in DM. The HCC treatment targets in these pathways, hyperinsulinemia, insulin resistance and IGF signaling pathways activation and pharmacological control of HCC related to DM were potential targets.
Zitieren
APA
Ara, C., Zaka, F., Batool, A., Khan, S. H., & Zafar, N. U. H. (2026). Mechanistic Insights into the Diabetes–Cirrhosis–Hepatocellular Carcinoma Axis: Molecular Mechanisms and Therapeutic Perspectives. Journal of Cancer Biomoleculars and Therapeutics, 3(2), 35-49. https://doi.org/10.62382/jcbt.v3i2.117
Vancouver
Ara C, Zaka F, Batool A, Khan SH, Zafar NUH. Mechanistic Insights into the Diabetes–Cirrhosis–Hepatocellular Carcinoma Axis: Molecular Mechanisms and Therapeutic Perspectives. Journal of Cancer Biomoleculars and Therapeutics. 2026;3(2):35-49. doi:10.62382/jcbt.v3i2.117
BibTeX
@article{Ara2026,
author = {Ara, Chaman and Zaka, Fazeela and Batool, Asma and Khan, Sajal Hafza and Zafar, Noor ul Huda},
title = {Mechanistic Insights into the Diabetes–Cirrhosis–Hepatocellular Carcinoma Axis: Molecular Mechanisms and Therapeutic Perspectives},
journal = {Journal of Cancer Biomoleculars and Therapeutics},
year = {2026},
volume = {3},
number = {2},
pages = {35--49},
doi = {10.62382/jcbt.v3i2.117}
}
EUVIMED